Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL
Bastian L, Beder T, Barz M, Bendig S, Bartsch L, Walter W, Wolgast N, Brändl B, Rohrandt C, Hansen B, Hartmann A, Iben K, Das Gupta D, Denker M, Zimmermann J, Wittig M, Chitadze G, Neumann M, Schneller F, Fiedler W, Steffen B, Stelljes M, Faul C, Schwartz S, Müller F, Cario G, Harder L, Haferlach C, Pfeifer H, Gökbuget N, Brüggemann M, Baldus C
BLOOD. 2024;143(14):1391-1398.

Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy
Fiedler W
BRIT J HAEMATOL. 2024;204(4):1135-1136.

Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
Pratz K, Jonas B, Pullarkat V, Thirman M, Garcia J, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon S, Wolach O, Yeh S, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli R, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo C
AM J HEMATOL. 2024;99(4):615-624.

The Clinical Significance of CD73 in Cancer
Bach N, Winzer R, Tolosa E, Fiedler W, Brauneck F
INT J MOL SCI. 2023;24(14):.

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
Brauneck F, Schmalfeldt B, Muschhammer J, Sturmheit T, Ackermann C, Haag F, Schulze Zur Wiesch J, Ding Y, Qi M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Wellbrock J
FRONT IMMUNOL. 2023;14:1250258.

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial
Döhner H, Weber D, Krzykalla J, Fiedler W, Kühn M, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Fransecky L, Koller E, Wulf G, Schleicher J, Ringhoffer M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Samra M, Machherndl-Spandl S, Basara N, Leis C, Schrade A, Kapp-Schwoerer S, Cocciardi S, Bullinger L, Thol F, Heuser M, Paschka P, Gaidzik V, Saadati M, Benner A, Schlenk R, Döhner K, Ganser A
LANCET HAEMATOL. 2023;10(7):e495-e509.

Palbociclib in Acute Leukemias With KMT2A-rearrangement: Results of AMLSG 23-14 Trial
Gaidzik V, Paschka P, Schlenk R, Weber D, Fröhling S, Krämer A, Wäsch R, Westermann J, Mayer K, de Wit M, Fiedler W, Benner A, Heuser M, Thol F, Döhner K, Ganser A, Döhner H
HEMASPHERE. 2023;7(5):e877.

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek M, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti C, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller P, Dörr J, Seifert M, Cadilha B, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner C, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S
NAT BIOTECHNOL. 2023;41(11):1618-1632.

A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia
Jonas B, Hou J, Roboz G, Alvares C, Jeyakumar D, Edwards J, Erba H, Kelly R, Röllig C, Fiedler W, Brackman D, Siddani S, Chyla B, Hilger-Rolfe J, Watts J
HEMATOL ONCOL. 2023;41(4):743-752.

Broadening the horizon: potential applications of CAR-T cells beyond current indications
Karsten H, Matrisch L, Cichutek S, Fiedler W, Alsdorf W, Block A
FRONT IMMUNOL. 2023;14:1285406.

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy
Klement P, Fiedler W, Gabdoulline R, Dallmann L, Wienecke C, Schiller J, Kandziora C, Teich K, Heida B, Büttner K, Brandes M, Funke C, Wichmann M, Othman B, Chromik J, Amberg S, Kebenko M, Schlipfenbacher V, Wilke A, Modemann F, Janning M, Serve H, Bokemeyer C, Theile S, Deppermann U, Kranich A, Ganser A, Thol F, Heuser M
ANN HEMATOL. 2023;102(2):323-328.

Regulation of coagulation activation in newly diagnosed AML by the heme enzyme myeloperoxidase
Langer F, Quick H, Beitzen-Heineke A, Janjetovic S, Mäder J, Lehr C, Bokemeyer C, Kuta P, Renné T, Fiedler W, Beckmann L, Klingler F, Rolling C
THROMB RES. 2023;229:155-163.

The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma - a single-center analysis
Modemann F, Ahmadi P, von Kroge P, Weidemann S, Bokemeyer C, Dierlamm J, Fiedler W, Ghandili S
LEUKEMIA LYMPHOMA. 2023;64(11):1801-1810.

Rezidivierte/refraktäre AML – Herausforderungen in Diagnostik und Therapie
Modemann F, Ghandili S, Bokemeyer C, Fiedler W
Kompendium ... Hämatologie/Onkologie. 2023;2023(21-27):21-27.

Therapie der rezidivierten/refraktären akuten myeloischen Leukämie: Aktuelle Behandlungsoptionen bei einem Rezidiv
Modemann F, Ghandili S, Bokemeyer C, Fiedler W
Im Fokus Onkologie. 2023;26(2):18-23.

Abdominal emergency surgery in patients with hematological malignancies: a retrospective single-center analysis
von Kroge P, Duprée A, Mann O, Izbicki J, Wagner J, Ahmadi P, Weidemann S, Adjallé R, Kröger N, Bokemeyer C, Fiedler W, Modemann F, Ghandili S
WORLD J EMERG SURG. 2023;18(1):12.

Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia
Wagner J, Al-Bazaz M, Forstreuter A, Hammada M, Hille J, Papingi D, Bokemeyer C, Fiedler W
BIOMEDICINES. 2023;12(1):.

TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
Brauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, da Costa Avelar P, Tsoka S, Bullinger L, Seubert E, Smit D, Bokemeyer C, Ackermann C, Wellbrock J, Haag F, Fiedler W
J IMMUNOTHER CANCER. 2022;10(12):.

Midostaurin plus intensive chemotherapy for younger and older Patients with AML and FLT3 internal tandem duplications
Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, Lübbert M, Kühn M, Schroeder T, Salwender H, Götze K, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler H, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik V, Theis F, Thol F, Heuser M, Schlenk R, Bullinger L, Saadati M, Benner A, Larson R, Stone R, Döhner K, Ganser A
BLOOD ADV. 2022;6(18):5345-5355.

Patientin mit therapieinduzierter sekundärer akuter myeloischer Leukämie (t-AML)
Fiedler W
2022.

Mebendazole's Conformational Space and Its Predicted Binding to Human Heat-Shock Protein 90
Fiedler W, Freisleben F, Wellbrock J, Kirschner K
J CHEM INF MODEL. 2022;62(15):3604-3617.

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia
Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz C, Esteve J, Mondal S, Rüter B, Burkard U, Osswald A, Blum W
HAEMATOLOGICA. 2022;107(12):2977-2982.

Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation
Ghandili S, Kluger M, Leitner T, Grahammer F, Kirchner L, Modemann F, Achilles E, Kreipe H, Klein J, Steinemann D, Wolschke C, Fischer L, Bokemeyer C, Fiedler W, Huber T, Alsdorf W, Mahmud M
BRIT J HAEMATOL. 2022;198(1):199-202.

Clinical features of hepatitis E infections in patients with hematologic disorders
Ghandili S, Lindhauer C, Pischke S, Zur Wiesch J, Von Kroge P, Polywka S, Bokemeyer C, Fiedler W, Kröger N, Ayuk F, Adjallé R, Modemann F
HAEMATOLOGICA. 2022;107(12):2870-2883.

Aktueller diagnostischer Standard und Risikostratifizierung der AML
Ghandili S, Modemann F, Oelrich J, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(7-8):10–15.

Diagnostic Utility of Bronchoalveolar Lavage in Patients with Acute Leukemia under Broad-Spectrum Anti-Infective Treatment
Ghandili S, von Kroge P, Simon M, Henes F, Rohde H, Hoffmann A, Lindeman N, Bokemeyer C, Fiedler W, Modemann F
CANCERS. 2022;14(11):.

Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia
Jonas B, Wei A, Recher C, DiNardo C, Jang J, Pratz K, Panayiotidis P, Montesinos P, Yeh S, Ivanov V, Fiedler W, Yamauchi T, Duan Y, Mendes W, Potluri J, Tews B, Ofran Y
AM J HEMATOL. 2022;97(8):E299-E303.

Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine
Klingler F, Alsdorf W, Ghandili S, Wolschke C, Brauneck F, Bokemeyer C, Fiedler W, Modemann F, Karagiannis P
LEUKEMIA LYMPHOMA. 2022;63(11):2645-2651.

AML-440 Prognosis of Molecularly-Defined Secondary Acute Myeloid Leukemia Patients
Mecklenbrauck R, Borchert N, Klement P, Funke C, Brandes M, Dallmann L, Fiedler W, Krauter J, Trummer A, Hertenstein B, Voβ A, Lübbert M, Gaidzik V, Döhner K, Döhner H, Ganser A, Thol F, Heuser M
CL LYMPH MYELOM LEUK. 2022;22(Suppl 2):S251-S252.

Erstlinientherapie intensiv-therapierbarer AML Patient*innen
Modemann F, Ghandili S, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(7-8):16-21.

Therapie der akuten Promyelozytenleukämie
Modemann F, Ghandili S, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(12):16–21.

Überblick zur Diagnostik und Therapie neu diagnostizierter Patienten mit AML
Modemann F, Ghandili S, Bokemeyer C, Fiedler W
Onkologie heute. 2022;2022(09):22-29.

Aktuelle Therapieoptionen bei rezidivierter/refraktärer AML
Modemann F, Ghandili S, Oelrich J, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(10):18-23.

COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress
Modemann F, Ghandili S, Schmiedel S, Weisel K, Bokemeyer C, Fiedler W
CANCERS. 2022;14(15):.

Die akute Promyelozytenleukämie - ein hämatologischer Notfall
Modemann F, Ghandili S, Zhurba I, Langer F, Bokemeyer C, Fiedler W
InFo Hämatologie + Onkologie. 2022;25(12):10–15.

Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia-A Single Center Analysis
Modemann F, Härterich S, Schulze Zur Wiesch J, Rohde H, Lindeman N, Bokemeyer C, Fiedler W, Ghandili S
ANTIBIOTICS-BASEL. 2022;11(2):.

COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies
Modemann F, Niederwieser C, Weisel K, Bokemeyer C, Fiedler W, Ghandili S
LEUKEMIA LYMPHOMA. 2022;63(3):664-671.

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
Ochsenreither S, Fiedler W, Conte G, Macchini M, Matos I, Habel B, Ahrens-Fath I, Raspagliesi F, Lorusso D, Keilholz U, Rolling C, Kebenko M, Klinghammer K, Saavedra O, Baumeister H, Zurlo A, Garralda E
ESMO OPEN. 2022;7(2):.

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
Pollyea D, DiNardo C, Arellano M, Pigneux A, Fiedler W, Konopleva M, Rizzieri D, Smith B, Shinagawa A, Lemoli R, Dail M, Duan Y, Chyla B, Potluri J, Miller C, Kantarjian H
CLIN CANCER RES. 2022;28(13):2753-2761.

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
Pratz K, Panayiotidis P, Recher C, Wei X, Jonas B, Montesinos P, Ivanov V, Schuh A, DiNardo C, Novak J, Pejsa V, Stevens D, Yeh S, Kim I, Turgut M, Fracchiolla N, Yamamoto K, Ofran Y, Wei A, Bui C, Benjamin K, Kamalakar R, Potluri J, Mendes W, Devine J, Fiedler W
BLOOD CANCER J. 2022;12(4):.

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy
Wei A, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting S, Hou J, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Jiang Q, Sun Y, Chyla B, Mendes W, DiNardo C
BLOOD. 2022;140(25):2754-2756.

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
Weimer P, Wellbrock J, Sturmheit T, Ferrer L, Ding Y, Menzel S, Witt M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Brauneck F
CELLS-BASEL. 2022;11(6):.

Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML
Brauneck F, Haag F, Woost R, Wildner N, Tolosa E, Rissiek A, Vohwinkel G, Wellbrock J, Bokemeyer C, Schulze Zur Wiesch J, Ackermann C, Fiedler W
ONCOIMMUNOLOGY. 2021;10(1):1930391.

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
Brauneck F, Seubert E, Wellbrock J, Schulze Zur Wiesch J, Duan Y, Magnus T, Bokemeyer C, Koch-Nolte F, Menzel S, Fiedler W
INT J MOL SCI. 2021;22(23):.

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
Brauneck F, Weimer P, Schulze zur Wiesch J, Weisel K, Leypoldt L, Vohwinkel G, Fritzsche B, Bokemeyer C, Wellbrock J, Fiedler W
FRONT MED-LAUSANNE. 2021;8:763773.

Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020
Brehm T, Heyer A, Roedl K, Jarczak D, Nierhaus A, Nentwich M, van der Meirschen M, Schultze A, Christner M, Fiedler W, Kröger N, Huber T, Klose H, Sterneck M, Jordan S, Kreuels B, Schmiedel S, Addo M, Huber S, Lohse A, Kluge S, Schulze Zur Wiesch J
J CLIN MED. 2021;10(11):.

Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza
Brehm T, van der Meirschen M, Hennigs A, Roedl K, Jarczak D, Wichmann D, Frings D, Nierhaus A, Oqueka T, Fiedler W, Christopeit M, Kraef C, Schultze A, Lütgehetmann M, Addo M, Schmiedel S, Kluge S, Schulze Zur Wiesch J
SCI REP-UK. 2021;11(1):.

Zytopenie-Mamgement akute myeloische Leukämie
Bullinger L, Fiedler W, Rieger C, Schliemann C
2021.

Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
Döhner H, Symeonidis A, Deeren D, Demeter J, Sanz M, Anagnostopoulos A, Esteve J, Fiedler W, Porkka K, Kim H, Lee J, Usuki K, D'Ardia S, Won Jung C, Salamero O, Horst H, Recher C, Rousselot P, Sandhu I, Theunissen K, Thol F, Döhner K, Teleanu V, DeAngelo D, Naoe T, Sekeres M, Belsack V, Ge M, Taube T, Ottmann O
HEMASPHERE. 2021;5(8):e617.

Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy
Efficace F, Platzbecker U, Breccia M, Cottone F, Carluccio P, Salutari P, Di Bona E, Borlenghi E, Autore F, Levato L, Finizio O, Mancini V, D'Ardia S, Schlenk R, Melillo L, Fumagalli M, Fiedler W, Beltrami G, Fracchiolla N, Bernardi M, Fazi P, Annibali O, Mayer K, Voso M, Vignetti M
BLOOD ADV. 2021;5(21):4370-4379.

Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow
Engel N, Reinert J, Borchert N, Panagiota V, Gabdoulline R, Thol F, Heuser M, Fiedler W
ANN HEMATOL. 2021;100(2):499-503.

Mebendazole Mediates Proteasomal Degradation of GLI Transcription Factors in Acute Myeloid Leukemia
Freisleben F, Modemann F, Muschhammer J, Stamm H, Brauneck F, Krispien A, Bokemeyer C, Kirschner K, Wellbrock J, Fiedler W
INT J MOL SCI. 2021;22(19):10670.

Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations
Heuser M, Heida B, Büttner K, Wienecke C, Teich K, Funke C, Brandes M, Klement P, Liebich A, Wichmann M, Neziri B, Chaturvedi A, Kloos A, Mintzas K, Gaidzik V, Paschka P, Bullinger L, Fiedler W, Heim A, Puppe W, Krauter J, Döhner K, Döhner H, Ganser A, Stadler M, Hambach L, Gabdoulline R, Thol F
BLOOD ADV. 2021;5(9):2294-2304.

Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
Heuser M, Smith B, Fiedler W, Sekeres M, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón J, Hoang C, O'Brien T, Ma W, Zeremski M, O'Connell A, Chan G, Cortes J
ANN HEMATOL. 2021;100(5):1181-1194.

Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
Heuser M, Smith B, Fiedler W, Sekeres M, Montesinos P, Leber B, Merchant A, Papayannidis C, Pérez-Simón J, Hoang C, O'Brien T, Ma W, Zeremski M, O'Connell A, Chan G, Cortes J
ANN HEMATOL. 2021;100(7):1917-1918.

Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone
Karagiannis P, Alsdorf W, Tallarek A, Blohm M, Oelrich J, Waizenegger J, Wolschke C, Hecher K, Singer D, Bokemeyer C, Fiedler W
BRIT J HAEMATOL. 2021;192(2):e60-e63.

Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
Reinert J, Beitzen-Heineke A, Wethmar K, Stelljes M, Fiedler W, Schwartz S
ANN HEMATOL. 2021;100(11):2727-2732.

Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
Schmalbrock L, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, Panina E, Blätte T, Herzig J, Skambraks S, Rücker F, Gaidzik V, Paschka P, Fiedler W, Salih H, Wulf G, Schroeder T, Lübbert M, Schlenk R, Thol F, Heuser M, Larson R, Ganser A, Stunnenberg H, Minucci S, Stone R, Bloomfield C, Döhner H, Döhner K, Bullinger L
BLOOD. 2021;137(22):3093-3104.

Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
Teich K, Krzykalla J, Kapp-Schwoerer S, Gaidzik V, Schlenk R, Paschka P, Weber D, Fiedler W, Kühn M, Schroeder T, Mayer K, Lübbert M, Ramachandran D, Benner A, Ganser A, Döhner H, Heuser M, Döhner K, Thol F
HAEMATOLOGICA. 2021;106(11):2986-2989.

High Mobility Group Box 1 (HMGB1) Induces Toll-Like Receptor 4-Mediated Production of the Immunosuppressive Protein Galectin-9 in Human Cancer Cells
Teo Hansen Selnø A, Schlichtner S, Yasinska I, Sakhnevych S, Fiedler W, Wellbrock J, Berger S, Klenova E, Gibbs B, Fasler-Kan E, Sumbayev V
FRONT IMMUNOL. 2021;12:.

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Wei A, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens D, Fiedler W, Pagoni M, Bergeron J, Ting S, Hou J, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo C
BLOOD CANCER J. 2021;11(10):163.

Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy
Wei A, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens D, Fiedler W, Pagoni M, Bergeron J, Ting S, Hou J, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo C
BLOOD CANCER J. 2021;11(10):171.

The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia
Wellbrock J, Behrmann L, Muschhammer J, Modemann F, Khoury K, Brauneck F, Bokemeyer C, Campeau E, Fiedler W
ANN HEMATOL. 2021;100(12):2933-2941.

Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19
Woo M, Haag F, Nierhaus A, Jarczak D, Roedl K, Mayer C, Brehm T, van der Meirschen M, Hennigs A, Christopeit M, Fiedler W, Karagiannis P, Burdelski C, Schultze A, Huber S, Addo M, Schmiedel S, Friese M, Kluge S, Schulze Zur Wiesch J
ISCIENCE. 2021;24(7):102752.

The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies
Behrmann L, Wellbrock J, Fiedler W
EXPERT OPIN THER TAR. 2020;24(5):451-462.

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih H, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso M, Ehninger G, Schlenk R, Lo-Coco F
LEUKEMIA. 2020;34(3):914-918.

Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
Cortes J, Heidel F, Fiedler W, Smith B, Robak T, Montesinos P, Candoni A, Leber B, Sekeres M, Pollyea D, Ferdinand R, Ma W, O'Brien T, O'Connell A, Chan G, Heuser M
J HEMATOL ONCOL. 2020;13(1):92.

A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia
Fiedler W, Chromik J, Amberg S, Kebenko M, Thol F, Schlipfenbacher V, Christine Wilke A, Modemann F, Janning M, Serve H, Ganser A, Bokemeyer C, Theile S, Deppermann U, Kranich A, Heuser M
BRIT J HAEMATOL. 2020;190(3):e169-e173.

Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia
Freisleben F, Behrmann L, Thaden V, Muschhammer J, Bokemeyer C, Fiedler W, Wellbrock J
INT J MOL SCI. 2020;21(14):.

Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients
Ghandili S, Pfefferle S, Roedl K, Sonnemann P, Karagiannis P, Boenisch O, Kluge S, Schmiedel S, Ittrich H, Rohde H, Lütgehetmann M, Weisel K, Bokemeyer C, Wichmann D, Fiedler W, Jarczak D, Modemann F
BLOOD ADV. 2020;4(23):5936-5941.

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results
Heuser M, Palmisiano N, Mantzaris I, Mims A, DiNardo C, Silverman L, Wang E, Fiedler W, Baldus C, Schwind S, Pardee T, Perl A, Cai C, Kaulfuss S, Lagkadinou E, Rentzsch C, Wagner M, Wilkinson G, Wu B, Jeffers M, Genvresse I, Krämer A
LEUKEMIA. 2020;34(11):2903-2913.

Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial
Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik V, Paschka P, Krönke J, Theis F, Rücker F, Teleanu M, Panina E, Jahn N, Herzig J, Kubanek L, Schrade A, Göhring G, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst H, Koller E, Wulf G, Schleicher J, Bentz M, Krauter J, Bullinger L, Krzykalla J, Benner A, Schlenk R, Thol F, Heuser M, Ganser A, Döhner H, Döhner K
BLOOD. 2020;136(26):3041-3050.

Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis
Karagiannis P, Sänger L, Alsdorf W, Weisel K, Fiedler W, Kluge S, Wichmann D, Bokemeyer C, Fuhrmann V
CANCERS. 2020;12(6):.

Successful Treatment of Delayed Methotrexate Clearance using Glucarpidase Dosed on Ideal Body Weight in Obese Patients
Krüger C, Engel N, Reinert J, Alsdorf W, Fiedler W, Dierlamm J, Bokemeyer C, Langebrake C
PHARMACOTHERAPY. 2020;40(5):479-483.

Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma
Oliveira-Ferrer L, Milde-Langosch K, Eylmann K, Rossberg M, Müller V, Schmalfeldt B, Witzel I, Wellbrock J, Fiedler W
INT J MOL SCI. 2020;21(2):.

Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
Schlenk R, Paschka P, Krzykalla J, Weber D, Kapp-Schwoerer S, Gaidzik V, Leis C, Fiedler W, Kindler T, Schroeder T, Mayer K, Lübbert M, Wattad M, Götze K, Horst H, Koller E, Wulf G, Schleicher J, Bentz M, Greil R, Hertenstein B, Krauter J, Martens U, Nachbaur D, Abu Samra M, Girschikofsky M, Basara N, Benner A, Thol F, Heuser M, Ganser A, Döhner K, Döhner H
J CLIN ONCOL. 2020;38(6):623-632.

Transforming growth factor beta type 1 (TGF-β) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells
Selnø A, Schlichtner S, Yasinska I, Sakhnevych S, Fiedler W, Wellbrock J, Klenova E, Pavlova L, Gibbs B, Degen M, Schnyder I, Aliu N, Berger S, Fasler-Kan E, Sumbayev V
AGING-US. 2020;12(23):23478-23496.

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
Wei A, Montesinos P, Ivanov V, DiNardo C, Novak J, Laribi K, Kim I, Stevens D, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou J, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P
BLOOD. 2020;135(24):2137-2145.

Implications of SARS-CoV-2 Infection and COVID-19 Crisis on Clinical Cancer Care: Report of the University Cancer Center Hamburg: Report of the University Cancer Center Hamburg
Weisel K, Morgner-Miehlke A, Petersen C, Fiedler W, Block A, Schafhausen P, Knobloch J, Bokemeyer C
ONCOL RES TREAT. 2020;43(6):307-313.

Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity
Yasinska I, Meyer N, Schlichtner S, Hussain R, Siligardi G, Casely-Hayford M, Fiedler W, Wellbrock J, Desmet C, Calzolai L, Varani L, Berger S, Raap U, Gibbs B, Fasler-Kan E, Sumbayev V
FRONT IMMUNOL. 2020;11:580557.

Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial
Bixby D, Noppeney R, Lin T, Cortes J, Krauter J, Yee K, Medeiros B, Krämer A, Assouline S, Fiedler W, Dimier N, Simmons B, Riehl T, Colburn D
BRIT J HAEMATOL. 2019;185(3):595-598.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Cortes J, Heidel F, Hellmann A, Fiedler W, Smith B, Robak T, Montesinos P, Pollyea D, DesJardins P, Ottmann O, Ma W, Shaik M, Laird A, Zeremski M, O'Connell A, Chan G, Heuser M
LEUKEMIA. 2019;33(2):379-389.

A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia
Döhner H, Müller-Tidow C, Lübbert M, Fiedler W, Krämer A, Westermann J, Bug G, Schlenk R, Krug U, Goeldner R, Hilbert J, Taube T, Ottmann O
BRIT J HAEMATOL. 2019;185(3):583-587.

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study
Hütter-Krönke M, Fiedler W, Kündgen A, Krauter J, von Lilienfeld-Toal M, Döhner H, Schlenk R
HAEMATOLOGICA. 2019;104(2):E63-E64.

AML: Klinische Bedeutung von Spleißvarianten und Spleiß-assoziierten Genmutationen
Janning M, Fiedler W
J Onkol - Z Onkol Fortb. 2019;2019(6):42-45.

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Rücker F, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik V, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst H, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk R, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K
BLOOD. 2019;134(19):1608-1618.

Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Schlenk R, Weber D, Fiedler W, Salih H, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze K, Horst H, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs H, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik V, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H
BLOOD. 2019;133(8):840-851.

Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Stamm H, Oliveira-Ferrer L, Grossjohann E, Muschhammer J, Thaden V, Brauneck F, Kischel R, Müller V, Bokemeyer C, Fiedler W, Wellbrock J
ONCOIMMUNOLOGY. 2019;8(12):e1674605.

3D in vitro system for measuring treatment responses to immunotherapy in CRC patients
Sturmheit T, Stamm H, Sutus Temovski T, Konczalla L, Brauneck F, Stange I, Köllmann S, Li J, Perez D, thastrup J, Wellbrock J, Fiedler W, Kupper J, Block A
J CLIN ONCOL. 2019.

The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia
Velthaus A, Cornils K, Hennigs J, Grüb S, Stamm H, Wicklein D, Bokemeyer C, Heuser M, Windhorst S, Fiedler W, Wellbrock J
CANCERS. 2019;11(11):.

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Wei A, Strickland S, Hou J, Fiedler W, Lin T, Walter R, Enjeti A, Tiong I, Savona M, Lee S, Chyla B, Popovic R, Salem A, Agarwal S, Xu T, Fakouhi K, Humerickhouse R, Hong W, Hayslip J, Roboz G
J CLIN ONCOL. 2019;37(15):1277-1284.

Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look
Behrmann L, Wellbrock J, Fiedler W
FRONT ONCOL. 2018;8:444.

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas
Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L
ESMO OPEN. 2018;3(2):e000303.

Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours
Fiedler W, Stoeger H, Perotti A, Gastl G, Weidmann J, Dietrich B, Baumeister H, Danielczyk A, Goletz S, Salzberg M, De Dosso S
ESMO OPEN. 2018;3(4):e000381.

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia
Gaidzik V, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst H, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk R, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K
LEUKEMIA. 2018;32(1):30-37.

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
Kebenko M, Goebeler M, Wolf M, Hasenburg A, Seggewiss-Bernhardt R, Ritter B, Rautenberg B, Atanackovic D, Kratzer A, Rottman J, Friedrich M, Vieser E, Elm S, Patzak I, Wessiepe D, Stienen S, Fiedler W
ONCOIMMUNOLOGY. 2018;7(8):e1450710.

Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)
Krauter J, Fiedler W, Schlenk R, Paschka P, Thol F, Lübbert M, Wattad M, Verbeek M, Könecke C, Neuhaus B, Papkalla A, Kebenko M, Janning M, Döhner K, Gaidzik V, Becker H, Greil C, Reimer P, Götze K, Döhner H, Ganser A, Heuser M
BRIT J HAEMATOL. 2018;183(2):235-241.

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial
Paschka P, Schlenk R, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik V, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst H, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih H, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H
LEUKEMIA. 2018;32(7):1621-1630.

Cortisol facilitates the immune escape of human acute myeloid leukemia cells by inducing latrophilin 1 expression
Sakhnevych S, Yasinska I, Bratt A, Benlaouer O, Gonçalves Silva I, Hussain R, Siligardi G, Fiedler W, Wellbrock J, Gibbs B, Ushkaryov Y, Sumbayev V
CELL MOL IMMUNOL. 2018;15(11):994-997.

Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option
Stamm H, Klingler F, Grossjohann E, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W
ONCOGENE. 2018;37(39):5269-5280.

Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer
Stamm H, Wellbrock J, Fiedler W
MAMM GENOME. 2018;29(11-12):694-702.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Büttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Göhring G, Schlegelberger B, Gaidzik V, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk R, Paschka P, Döhner K, Döhner H, Ganser A, Heuser M
BLOOD. 2018;132(16):1703-1713.

Acute hepatitis as a prequel to very severe aplastic anemia
Weiler-Normann C, Hartl J, Weidemann S, von Pein U, Fiedler W, Schramm C, Brinkert F, Kröger N, Christopeit M
Z GASTROENTEROL. 2018;56(1):51-54.

Highly specific targeting of human acute myeloid leukaemia cells using pharmacologically active nanoconjugates
Yasinska I, Ceccone G, Ojea-Jimenez I, Ponti J, Hussain R, Siligardi G, Berger S, Fasler-Kan E, Bardelli M, Varani L, Fiedler W, Wellbrock J, Raap U, Gibbs B, Calzolai L, Sumbayev V
NANOSCALE. 2018;10(13):5827-5833.

High mobility group box 1 (HMGB1) acts as an "alarmin" to promote acute myeloid leukaemia progression
Yasinska I, Gonçalves Silva I, Sakhnevych S, Ruegg L, Hussain R, Siligardi G, Fiedler W, Wellbrock J, Bardelli M, Varani L, Raap U, Berger S, Gibbs B, Fasler-Kan E, Sumbayev V
ONCOIMMUNOLOGY. 2018;7(6):e1438109.

The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia
Both A, Krauter J, Damm F, Thol F, Göhring G, Heuser M, Ottmann O, Lübbert M, Wattad M, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Brugger W, Schlegelberger B, Heil G, Ganser A, Wagner K
ANN HEMATOL. 2017;96(6):895-904.

The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells
Gonçalves Silva I, Yasinska I, Sakhnevych S, Fiedler W, Wellbrock J, Bardelli M, Varani L, Hussain R, Siligardi G, Ceccone G, Berger S, Ushkaryov Y, Gibbs B, Fasler-Kan E, Sumbayev V
EBIOMEDICINE. 2017;22:44-57.

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): A study of the German-Austrian AML study group (AMLSG)
Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik V, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne C, Horst H, Lübbert M, Ganser A, Schlenk R, Döhner H, Döhner K, Paschka P
LEUKEMIA. 2017;31(4):1012-1015.

Zielgerichtete Therapie und Immuntherapie bei der AML
Janning M, Fiedler W
J Onkol - Z Onkol Fortb. 2017;5(05):184-191.

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih H, Held G, Köhne C, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst H, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk R
BLOOD CANCER J. 2017;7(5):e564.

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia
Latuske E, Stamm H, Klokow M, Vohwinkel G, Muschhammer J, Bokemeyer C, Jücker M, Kebenko M, Fiedler W, Wellbrock J
ONCOTARGET. 2017;8(17):29187-29201.

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih H, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs H, Horst H, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik V, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk R
ANN HEMATOL. 2017;96(12):1993-2003.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: A study of the AML study group (AMLSG)
Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih H, Wattad M, Lübbert M, Brandts C, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani E, Fozza C, D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk R, Lo-Coco F
J CLIN ONCOL. 2017;35(6):605-612.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
Schlenk R, Frech P, Weber D, Brossart P, Horst H, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih H, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik V, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H
LEUKEMIA. 2017;31(5):1217-1220.

SHIP1, but not an AML-derived SHIP1 mutant, suppresses myeloid leukemia growth in a xenotransplantation mouse model
Täger M, Horn S, Latuske E, Ehm P, Schaks M, Nalaskowski M, Fehse B, Fiedler W, Stocking C, Wellbrock J, Jücker M
GENE THER. 2017;24(11):749-753.

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis
Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichmann M, Chaturvedi A, Fabisch J, Gaidzik V, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk R, Döhner K, Döhner H, Ganser A, Heuser M
LEUKEMIA. 2017;31(6):1286-1295.

Relevance of the Hedgehog pathway in T-cell acute lymphoblastic leukemia
Wellbrock J, Fiedler W
TRANSL CANCER RES. 2017;6(Suppl 2):286-291.

Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia
Degwert N, Latuske E, Vohwinkel G, Stamm H, Klokow M, Bokemeyer C, Fiedler W, Wellbrock J
EUR J HAEMATOL. 2016;97(3):239-44.

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas
Fiedler W, DeDosso S, Cresta S, Weidmann J, Tessari A, Salzberg M, Dietrich B, Baumeister H, Goletz S, Gianni L, Sessa C
EUR J CANCER. 2016;63:55-63.

Akute Myeloische Leukämie.
Fiedler W, Janning M
Aktuelle Gesundheitsnachrichten . 2016.

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
Hütter-Krönke M, Benner A, Döhner K, Krauter J, Weber D, Moessner M, Köhne C, Horst H, Schmidt-Wolf I, Rummel M, Götze K, Koller E, Petzer A, Salwender H, Fiedler W, Kirchen H, Haase D, Kremers S, Theobald M, Matzdorff A, Ganser A, Döhner H, Schlenk R
HAEMATOLOGICA. 2016;101(7):839-45.

Hodgkin's lymphoma as a rare variant of Richter's transformation in chronic lymphocytic leukemia: A case report and review of the literature
Janjetovic S, Bernd H, Bokemeyer C, Fiedler W
MOL CLIN ONCOL. 2016;4(3):390-392.

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study
Schlenk R, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih H, Kündgen A, Horst H, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne C, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik V, Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H
ANN HEMATOL. 2016;95(12):1931-1942.

Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone
Schroeder M, Viezens L, Wellbrock J, Fiedler W, Ruether W, Algenstaedt P, Hansen-Algenstaedt N, Schäfer C
J SURG ONCOL. 2016;113(5):515-21.

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: A study of the AML study group (AMLSG)
Theis F, Corbacioglu A, Gaidzik V, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne C, Germing U, Brossart P, Horst H, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih H, Krauter J, Schlenk R, Döhner K
LEUKEMIA. 2016;30(11):2248-2250.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia
Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, Gomez-Roca C, Papayannidis C, Kebenko M, Paschka P, Christen R, Guarin E, Bröske A, Baehner M, Brewster M, Walz A, Michielin F, Runza V, Meresse V, Recher C
ONCOTARGET. 2016;7(22):32532-42.

The Rare Occurrence of the Translocation t(8;14) in Chronic Lymphatic Leukemia: Case Report and Review of the Literature
Coym A, Janjetovic S, Bokemeyer C, Fiedler W
Ann Hematol Oncol. 2015;2(5):1039.

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations
Fiedler W, Kayser S, Kebenko M, Janning M, Krauter J, Schittenhelm M, Götze K, Weber D, Göhring G, Teleanu V, Thol F, Heuser M, Döhner K, Ganser A, Döhner H, Schlenk R
BRIT J HAEMATOL. 2015.

ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts
Kebenko M, Drenckhan A, Gros S, Jücker M, Grabinski N, Ewald F, Grottke A, Schultze A, Izbicki J, Bokemeyer C, Wellbrock J, Fiedler W
CELL SIGNAL. 2015;27(2):373-81.

Thrombin generation in a patient with an acquired high-titre factor V inhibitor
Schmidt D, Steinhagen F, Schnabel C, Spath B, Holstein K, Fiedler W, Bokemeyer C, Renné T, Langer F
BLOOD COAGUL FIBRIN. 2015;26(1):81-87.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

Intrinsic BMP Antagonist Gremlin-1 as a Novel Circulating Marker in Pulmonary Arterial Hypertension
Wellbrock J, Harbaum L, Stamm H, Hennigs J, Schulz B, Klose H, Bokemeyer C, Fiedler W, Lüneburg N
LUNG. 2015.

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Wellbrock J, Latuske E, Köhler J, Wagner K, Stamm H, Vettorazzi E, Vohwinkel G, Klokow M, Uibeleisen R, Ehm P, Riecken K, Loges S, Thol F, Schubert C, Amling M, Jücker M, Bokemeyer C, Heuser M, Krauter J, Fiedler W
CLIN CANCER RES. 2015.

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein J, Lepretre S, Reman O, Turlure P, Ottmann O, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk R, Voss F, Taube T, Fritsch H, Maertens J
BLOOD. 2014;124(9):1426-33.

Akute myeloische Leukämie –bestmögliche Behandlung.
Fiedler W, Janning M, Kebenko M, Weidmann J, Janjetovic S, Bokemeyer C
Hamb Ärztebl. 2014;68:11-17.

Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development
Janning M, Fiedler W
FUTURE ONCOL. 2014;10(7):1157-65.

New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules
Pircher A, Wellbrock J, Fiedler W, Heidegger I, Gunsilius E, Hilbe W
NEURO-ONCOLOGY. 2014;86(1):46-52.

Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia
Thol F, Scherr M, Kirchner A, Shahswar R, Battmer K, Kade S, Chaturvedi A, Koenecke C, Stadler M, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Bug G, Ottmann O, Hofmann W, Kröger N, Fiedler W, Schlenk R, Döhner K, Döhner H, Krauter J, Eder M, Ganser A, Heuser M
HAEMATOLOGICA. 2014.

Overexpression of Gremlin-1 in Patients with Loeys-Dietz Syndrome: Implications on Pathophysiology and Early Disease Detection
Wellbrock J, Sheikhzadeh S, Oliveira Ferrer L, Stamm H, Hillebrand M, Keyser B, Klokow M, Vohwinkel G, Bonk V, Otto B, Streichert T, Balabanov S, Hagel C, Rybczynski M, Bentzien F, Bokemeyer C, Kodolitsch Y, Fiedler W
PLOS ONE. 2014;9(8):e104742.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

Acute megakaryoblastic leukemia in a patient with xeroderma pigmentosum: discussion of pathophysiological, prognostic, and toxicological aspects.
Janjetovic S, Bacher U, Haalck T, Janning M, Bokemeyer C, Fiedler W
ACTA HAEMATOL-BASEL. 2013;129(2):121-125.

Late recurrence of a pineal germinoma 14 years after radiation and chemotherapy: a case report and review of the literature
Janjetovic S, Bokemeyer C, Fiedler W, Frenzel T, Calaminus G, Honecker F
ONKOLOGIE. 2013;36(6):371-3.

Chylothorax in a patient with Hodgkin's lymphoma: a case report and review of the literature
Janjetovic S, Janning M, Daukeva L, Bokemeyer C, Fiedler W
TUMORI J. 2013;99(3):e96-9.

Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando S, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih H, Cazzola M, Melillo L, Carella A, Brandts C, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp M, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk R, Platzbecker U
NEW ENGL J MED. 2013;369(2):111-21.

Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway
Oliveira Ferrer L, Wellbrock J, Bartsch U, Penas E, Hauschild J, Klokow M, Bokemeyer C, Fiedler W, Schuch G
MOL CANCER. 2013;12(1):144.

Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia.
Thol F, Winschel C, Sonntag A, Damm F, Wagner K, Chaturvedi A, Göhring G, Schlegelberger B, Lübbert M, Fiedler W, Kirchner H, Krauter J, Ganser A, Heuser M
ANN HEMATOL. 2013;92(3):315-323.

Critical imbalance of TNF-α and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment.
Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M
ACTA HAEMATOL-BASEL. 2012;128(2):69-72.

The metabolite 3-hydroxiglutaric acid effectively reduces glioblastoma growth in vivo by affecting the structural integrity of tumor vasculature.
Oliveira-Ferrer L, Wellbrock J, Balabanov M, Klockow M, Hauschild J, Bokemeyer C, Fiedler W, Ergun S, Schuch G
CANCER LETT. 2012;326(2):161-167.

VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma
Schultze A, Ben-Batalla I, Riethdorf S, Bubenheim M, Yekebas E, Erbersdobler A, Reichelt U, Harms-Effenberger K, Schmidt T, Izbicki J, Bokemeyer C, Pantel K, Fiedler W, Loges S
CLIN EXP METASTAS. 2012;29(8):879-887.

CD146: a new partner for VEGFR2.
Wellbrock J, Fiedler W
BLOOD. 2012;120(11):2164-2165.

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Grosshennig A, Hamwi I, Thol F, Surdziel E, Fiedler W, Lübbert M, Kanz L, Reuter C, Heil G, Delwel R, Löwenberg B, Valk P, Krauter J, Ganser A
BLOOD. 2011;117(17):4561-4568.

Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
Damm F, Oberacker T, Thol F, Surdziel E, Wagner K, Chaturvedi A, Morgan M, Bomm K, Göhring G, Lübbert M, Kanz L, Fiedler W, Schlegelberger B, Heil G, Schlenk R, Döhner K, Döhner H, Krauter J, Ganser A, Heuser M
J CLIN ONCOL. 2011;29(6):682-689.

Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.
Desar [, Ingrid M, Herpen v, Carla M, Asten v, Jack J, Fiedler W, Walter [, Marreaud [, Sandrine [, Timmer-Bonte [, Johanna N, Ter V, Edwin G, Lambiase [, Antonio [, Bordignon [, Claudio [, Heerschap [, Arend [, Laarhoven v, Hanneke W
EUR J RADIOL. 2011;80(3):655-661.

Phase I trial of SU14813 in patients with advanced solid malignancies.
Fiedler W, Giaccone G, Lasch P, van der Horst I, Brega N, Courtney R, Abbattista A, Shalinsky D, Bokemeyer C, Boven E
ANN ONCOL. 2011;22(1):195-201.

A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
Grünwald V, Desar I, Haanen J, Fiedler W, Mouritzen U, Olsen M, Herpen v, Carla M
ACTA ONCOL. 2011;50(1):121-126.

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Hu-Lowe D, Chen E, Zhang L, Watson K, Mancuso P, Lappin P, Wickman G, Chen J, Wang J, Jiang X, Amundson K, Simon R, Erbersdobler A, Bergqvist S, Feng Z, Swanson T, Simmons B, Lippincott J, Casperson G, Levin W, Stampino C, Shalinsky D, Ferrara K, Fiedler W, Bertolini F
CANCER RES. 2011;71(4):1362-1373.

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.
Kobold S, Isernhagen J, Hübel K, Kilic N, Bogner C, Frickhofen N, Bokemeyer C, Fiedler W
BONE MARROW TRANSPL. 2011;46(8):1053-1056.

Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia
Otten J, Schmitz L, Vettorazzi E, Schultze A, Marx A, Simon R, Krauter J, Loges S, Sauter G, Bokemeyer C, Fiedler W
LEUKEMIA. 2011;25(2):375-9.

Primary tumor dependent inhibition of tumor growth, Angio-Genesis, and perfusion of secondary breast cancer in bone.
Schäfer C, Schröder M, Fuhrhop I, Viezens L, Wellbrock J, Fiedler W, Rüther W, Hansen-Algenstaedt N
J ORTHOP RES. 2011;29(8):1251-1258.

Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.
Schimmer A, Herr W, Hänel M, Borthakur G, Frankel A, Horst H, Martin S, Kassis J, Desjardins P, Seiter K, Fiedler W, Noppeney R, Giagounidis A, Jacob C, Jolivet J, Tallman M, Koschmieder S
CL LYMPH MYELOM LEUK. 2011;11(5):433-438.

Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.
Schultze A, Fiedler W
ANTI-CANCER AGENT ME. 2011;11(7):593-599.

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M
J CLIN ONCOL. 2011;29(21):2889-2896.

Clinical experience with antiangiogenic therapy in leukemia.
Wellbrock J, Fiedler W
CURR CANCER DRUG TAR. 2011;11(9):1053-1068.

Isolated limb perfusion with melphalan for the treatment of intractable primary cutaneous diffuse large B-cell lymphoma leg type.
Kobold S, Kilic N, Luetkens T, Bokemeyer C, Fiedler W
ACTA HAEMATOL-BASEL. 2010;123(3):179-181.

Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
Laarhoven v, Fiedler W, Fiedler W, Desar I, Asten v, Jack J, Marréaud S, Lacombe D, Govaerts A, Bogaerts J, Lasch P, Timmer-Bonte J, Lambiase A, Bordignon C, Punt C, Heerschap A, Herpen v, Carla M
CLIN CANCER RES. 2010;16(4):1315-1323.

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.
Marx A, Burandt E, Choschzick M, Simon R, Yekebas E, Kaifi J, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki J
HUM PATHOL. 2010;41(11):1577-1585.

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.
Marx A, Zielinski M, Kowitz C, Dancau A, Thieltges S, Simon R, Choschzick M, Yekebas E, Kaifi J, Mirlacher M, Atanackovic D, Brümmendorf T, Fiedler W, Bokemeyer C, Izbicki J, Sauter G
HISTOPATHOLOGY. 2010;57(3):418-426.

Microcirculation of secondary bone tumors in vivo: the impact of minor surgery at a distal site.
Schäfer C, Fuhrhop I, Schröder M, Viezens L, Wellbrock J, Fiedler W, Rüther W, Hansen-Algenstaedt N
J ORTHOP RES. 2010;28(11):1515-1521.

Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.
Schultze A, Fiedler W
EXPERT OPIN INV DRUG. 2010;19(6):777-788.

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A
BLOOD. 2010;116(4):614-616.

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor.
Wagner K, Damm F, Göhring G, Görlich K, Heuser M, Schäfer I, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Brugger W, Zucknick M, Schlegelberger B, Heil G, Ganser A, Krauter J
J CLIN ONCOL. 2010;28(14):2356-2364.

Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?
Wellbrock J, Bokemeyer C, Fiedler W
J ONCOL. 2010;2010:317068.

[28-year old female patient with respiratory insufficiency, elevated liver enzymes, pancytopenia and fever].
Wolschke C, Fiedler W, Habermann C, Janka-Schaub G, Kluge S
INTERNIST. 2010;51(11):1434-1438.

Single Nucleotide Polymorphism in the Mutational Hotspot of WT1 Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia.
Damm F, Heuser M, Morgan M, Yun H, Großhennig A, Göhring G, Schlegelberger B, Döhner K, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Döhner H, Heil G, Ganser A, Krauter J
J CLIN ONCOL. 2009.

An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
Fiedler W, Mesters R, Heuser M, Ehninger G, Berdel W, Zirrgiebel U, Robertson J, Puchalski T, Collins B, Jürgensmeier J, Serve H
LEUKEMIA RES. 2009.

Primary NK/T cell lymphoma nasal type of the stomach with skin involvement: a case report
Kobold S, Merz H, Tiemann M, Mahuad C, Bokemeyer C, Koop I, Fiedler W
RARE TUMORS. 2009;1(2):173-175.

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Langenberg M, Herpen v, Carla M, Johann D, Schellens J, Unger C, Hoekman K, Fiedler W, Fiedler W, Drevs J, Florence L, Fielding A, Robertson J, Voest E
J CLIN ONCOL. 2009;27(36):6152-6159.

Reduced proliferation of CD34(+) cells from patients with acute myeloid leukemia after gene transfer of INPP5D.
Metzner A, Precht C, Fehse B, Fiedler W, Stocking C, Günther A, Mayr G, Jücker M
GENE THER. 2009;16(4):570-573.

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Ocheni S, Iwanski G, Schafhausen P, Zander A, Ayuketang Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brümmendorf T, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2009;50(4):551-558.

TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.
Schultze A, Decker S, Wellbrock J, Horst A, Vohwinkel G, Schuch G, Bokemeyer C, Loges S, Fiedler W
INVEST NEW DRUG. 2009.

Prognostic implication of expression of Angiopoietin-2 in acute myeloid leukemia.
Fiedler W, Schuch G, Loges S
LEUKEMIA RES. 2008;32(6):843-844.

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A, Balabanov S, von Amsberg G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf T
BLOOD. 2008;111(8):4355-4364.

PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A, Balabanov S, von Amsberg G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf T
LEUKEMIA RES. 2008;32(12):1857-1865.

Esophageal squamous cell carcinoma presenting with extensive skin lesions: a case report
Iwanski G, Block A, von Amsberg G, Münch J, Claus S, Fiedler W, Bokemeyer C
J Med Case Rep. 2008;2:115.

Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Oliveira-Ferrer L, Hauschild J, Fiedler W, Bokemeyer C, Nippgen J, Celik I, Schuch G
J EXP CLIN CANC RES. 2008;27:86.

Time-course-dependent microvascular alterations in a model of myeloid leukemia in vivo.
Schäfer C, Krause M, Fuhrhop I, Schröder M, Algenstaedt P, Fiedler W, Rüther W, Hansen-Algenstaedt N
LEUKEMIA. 2008;22(1):59-65.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón J, Simon-Perez J, Gutierrez N, Fiedler W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Murga-Penas E, Dierlamm J, Ayuketang Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Miguel J, Nagler A, Kröger N
LEUKEMIA. 2008;22(6):1250-1255.

Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative.
Wellbrock J, Schultze A, Schafhausen P, Otterstetter S, Dierlamm J, Bokemeyer C, Brümmendorf T, Fiedler W, Loges S
BRIT J HAEMATOL. 2008;142(1):115-118.

[Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma]
Bartsch G, Eggert K, Soker S, Fiedler W, Laack E, Volkmer B, Gschwend J, Bokemeyer C, Hautmann R, Schuch G
UROLOGE. 2007;46(9):1289-1290.

CFU-EC: how they were originally defined.
Gehling U, Ergün S, Fiedler W
BLOOD. 2007;110(3):1073.

Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
Grünwald V, Heinzer H, Fiedler W
ONKOLOGIE. 2007;30(10):519-524.

Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro.
Loges S, Butzal M, Wellbrock J, Schweizer M, Fischer U, Bokemeyer C, Hossfeld D, Schuch G, Fiedler W
BIOCHEM BIOPH RES CO. 2007;357(4):1016-1020.

Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis.
Loges S, Clausen H, Reichelt U, Bubenheim M, Erbersdobler A, Schurr P, Yekebas E, Schuch G, Izbicki J, Pantel K, Bokemeyer C, Fiedler W
CLIN CANCER RES. 2007;13(1):76-80.

Letzte Aktualisierung aus dem FIS: 20.04.2024 - 00:48 Uhr